Despite centuries of medical use and several modern studies, 80 years of cannabis (Cannabis sativa, Cannabaceae) prohibition have left clinicians undereducated about its therapeutic uses. A 2017 US study found that 89.5% of surveyed residents and fellows felt unprepared to prescribe cannabis and just 35.5% felt prepared to answer patients’ questions about it. Only 9% of US medical schools include clinical cannabis content in curricula.* While there is a lack of randomized controlled trials (RCTs) in cannabis therapeutics, researchers and caregivers are recognizing RCTs’ limitations in applicability to individual patients, who may be better served by individualized evidence-based practices. Cannabis’ effects vary depending on many factors. It is desirable to find a “sweet spot” of dosing that provides symptom relief without adverse effects (AEs) like unwanted euphoria. The authors combine a review of the literature and their own clinical observations to offer guidance on Good Clinical Practices (GCPs)…